Each record shows the signal, who owns it, what is still unknown, what intervention could be tested and what evidence would be required before calling anything recovered.
Scale matters, but so do evidence quality, recoverability and whether success can be measured.
Test: Two-way reminders, cancellation friction reduction, risk prediction, intelligent backfill and specialty-specific access support.
Test: Daily discharge constraint coding, cross-system escalation, predictive discharge planning and earlier activation of downstream services.
Test: Closed-loop repeat ordering with stock confirmation, medication-change reconciliation and pharmacist review of flagged anomalies.
Test: Push alerts, easier cancellation, short-notice waitlists and risk-based reminder intensity.
The headline remains visible. Ownership, missing data, intervention and verification logic sit behind each record.
Period: 2023/24 benchmark · Confidence: High · Recoverability: High · Trend: Mixed
Owner: Provider elective operations
Loss mechanism: Clinical slots are created, staffed and scheduled but remain unused when patients do not attend and capacity cannot be backfilled.
Missing data: Reason for each DNA, notice period, reminder exposure, transport or access barrier, whether slot was backfilled, specialty-level avoidability.
Intervention: Two-way reminders, cancellation friction reduction, risk prediction, intelligent backfill and specialty-specific access support.
Verification: DNA rate, backfill rate, extra patients seen, avoided idle clinician minutes and cost per recovered slot.
Stage: Intervene
Source: NHS England, Reforming elective care / AI expansion ↗Period: 2025/26 plan · Confidence: High · Recoverability: High · Trend: Mixed
Owner: Acute, community and social care system
Loss mechanism: Beds remain occupied after acute need has ended because downstream care, transport, medicines, equipment or coordination is not ready.
Missing data: Primary delay reason per patient-day, responsible dependency, avoidability, handoff latency and repeated causes by locality.
Intervention: Daily discharge constraint coding, cross-system escalation, predictive discharge planning and earlier activation of downstream services.
Verification: Bed days beyond ready date, median delay by cause, same-day discharge after readiness and verified bed capacity released.
Stage: Intervene
Source: NHS England, Urgent and emergency care plan 2025/26 ↗Period: Historic waste estimate + current ordering scale · Confidence: Medium · Recoverability: High · Trend: Unknown
Owner: Primary care, pharmacy and medicines optimisation
Loss mechanism: Repeat supply can continue despite stock remaining at home, dose changes, discontinuation, admission/discharge changes or duplicated ordering.
Missing data: Patient-held stock, actual consumption, recent dose changes, discontinuation timing, hospital discharge reconciliation and item-level avoidability.
Intervention: Closed-loop repeat ordering with stock confirmation, medication-change reconciliation and pharmacist review of flagged anomalies.
Verification: Avoided items, avoided spend, intervention acceptance, patient safety events and verified reduction in unused medicines.
Stage: Observe
Source: NHS England medicines waste / NHS App repeat prescription reporting ↗Period: 2025 · Confidence: High · Recoverability: High · Trend: Unknown
Owner: Primary care networks and practices
Loss mechanism: Millions of booked primary-care appointments are lost after capacity has already been reserved.
Missing data: Reasons for non-attendance, reminder status, lead time, patient access barriers and whether slots could be reallocated.
Intervention: Push alerts, easier cancellation, short-notice waitlists and risk-based reminder intensity.
Verification: DNA rate, reclaimed appointments, same-day backfill, clinician minutes recovered and patient wait reduction.
Stage: Detect
Source: NHS England, Tap the NHS App ↗Period: 2020 model · Confidence: High · Recoverability: Medium · Trend: Unknown
Owner: Pharmacy aseptic services and clinical pathways
Loss mechanism: Injectable medicines can consume scarce pharmacy, nursing, cleanroom and bed capacity when preparation, presentation or treatment setting is suboptimal.
Missing data: True cost per administered dose, prepared-but-unused doses, waiting time, local procurement variation, nurse preparation time and suitability for ready-to-administer routes.
Intervention: True pathway costing, route/formulation substitution, dose banding, standardisation, hub-and-spoke supply and prepared-dose waste detection.
Verification: Nursing minutes released, aseptic capacity released, bed days avoided, unused doses and verified cash/capacity benefit.
Stage: Detect
Source: DHSC, Transforming NHS pharmacy aseptic services in England ↗Period: 2025/26 · Confidence: Medium · Recoverability: High · Trend: Improving
Owner: Surgical divisions and theatre operations
Loss mechanism: Lists lose capacity through late starts, overruns, cancellations, turnaround delay, staffing constraints and missing pre-op readiness.
Missing data: Minute-level loss reason with ownership, preventability, patient readiness, staffing/equipment cause and whether lost time could have been converted into another case.
Intervention: Standard minute-level delay taxonomy, predictive list planning, readiness checks and real-time escalation for recoverable gaps.
Verification: Touch-time utilisation, late-start minutes, cancellation rate, cases per list and recovered theatre minutes.
Stage: Detect
Source: NHS England productivity updates ↗Period: 2024/25 to 2025/26 · Confidence: High · Recoverability: Medium · Trend: Improving
Owner: Trust workforce and finance
Loss mechanism: Temporary staffing can be necessary, but avoidable reliance creates premium spend and workforce instability.
Missing data: Shift-level reason for agency use, failed bank fill, roster gap cause, specialty premium, vacancy age and avoidable versus clinically necessary agency use.
Intervention: Shift-level causality, bank-first rules, predictive rostering, retention actions and targeted recruitment in repeated hot spots.
Verification: Agency spend, premium over bank/substantive rate, unfilled shifts, repeated gap causes and sustained reduction without safety deterioration.
Stage: Verify
Source: NHS England, Month 12 financial position 2025/26 ↗Period: 2024/25 · Confidence: High · Recoverability: Low · Trend: Worsening
Owner: Provider pharmacy, finance and commissioning
Loss mechanism: A large adverse variance exists, but it should not be labelled waste without separating demand, price, innovation, case-mix and avoidable variation.
Missing data: Price-volume-mix decomposition, new therapy impact, procurement variance, unwarranted clinical variation and avoidable versus clinically justified growth.
Intervention: Decompose variance before action; then target procurement variation, biosimilar uptake, pathway redesign and unwarranted prescribing variation where evidenced.
Verification: Variance explained, avoidable component identified, procurement savings and prescribing change with outcome safeguards.
Stage: Observe
Source: NHS England, Financial performance report 2024/25 Q4 ↗